SAB BIOTHERAPEUTICS, INC. Payments for Securities Purchased under Agreements to Resell
SAB BIOTHERAPEUTICS, INC. (SABS) reported Payments for Securities Purchased under Agreements to Resell of $817.06 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForSecuritiesPurchasedUnderAgreementsToResell · last filed 2022-11-14
- SAB BIOTHERAPEUTICS, INC. payments for securities purchased under agreements to resell for the quarter ending 2022-09-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. payments for securities purchased under agreements to resell for the quarter ending 2022-06-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. payments for securities purchased under agreements to resell for the quarter ending 2022-03-31 was $817.06K.
| Period end | Payments for Securities Purchased under Agreements to Resell 3 month | Payments for Securities Purchased under Agreements to Resell 6 month | Payments for Securities Purchased under Agreements to Resell 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $817.06K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $817.06K 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $817.06K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |